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and is recommendcd when cascs ofAspergillus infection are detected but they
are not recommended on routine basis. Surveillance cultures of high risk
patients, in search ofAspergillus or Candida. may guide thc administration of
preemptive or prophylactic antifungals, However, the real efficacy of this
surveillance practices, remains to be defined.
511 - Is malareia being rolled back
ITuS31 Malaria vaccine development Approaches and status
J. Cohen
SmithKlitle Beecham Biologicals, Rixensart. Belgium
Malaria remains onc ofthc world most deadly diseases. The World Health
Organization estimates that there are 300 to 500 million clinical cases of
malaria annually, causing 1.1 to 1.7 million deaths. The vast majority of
deaths occurs among children under 5 years ofage and 90% ofmalaria cases
are in sub-Saharan Africa.
While various control mcasures can contribute to amelioratc this situa-
tion, it is generally accepted that. in the long run, vaccines are likely to be the
most effective and cost efficient way to fight this disease. Fortunately, there
exist today convincing preclinical and preliminary clinical data suggesting
that the development of a malaria vaccine is needed feasible.
In the first part of this presentation, we will describe the various
approaches rescarchers in this field have employed in their attempts to
develop vaccines targeting the different stages of the Plasmodium falciparum
parasite life cycle. The rationale and results obtained with each approach will
be described.
We will then focus on one promising malaria vaccine candidate, desig-
nated R TS, S/SBAS2, that has been developed by SmithKline Beecham
Biologicals and its collaborators. This vaccine has recently yielded unprece-
dented efficacy results in clinical trials conducted both under laboratory and
natural (field) challenge conditions. Avenues for further development and
improvement of this vaccine will be described.
!TuS41 Transmission blocking drugs or vacdnes for control of
malaria
R. Sauerwein
University Medical Centre St Radboud, Dept ofMedical Microbiology,
Nijmegftl, Netherlands
The rate of malaria transmission is an important denominator in the
epidemiology of clinical of malaria. Malaria parasit.... arc distributed in the
population by Plasmodium-infected Anopheles mosquitoes; the number of
infected mosquitoes can vary significantly per geographical area. The more
intense the transmission, the younger the age at which malaria immunity and
protection from lethal diseasc is acquired. Infectiousness ofthe human host to
mosquitoes is determin..-d by the presence of sexual stages (gametocytes
[gct]) in the circulation. Transmission-blocking (TB)-vaccines or drugs aim
at a reduction of the human infectious reservoir by killing or inactivating
gct's and form an important component in malaria control. TB vaccines and
drugs can directly reduce morbidity and mortality but also may act as an
adjunct to other malaria vaccines by reducing the spread ofresistant strains.
TB-immunity induced by vaccines is antibody-mediated and a number of
target molecules on the parasite membrane have been identified. Some
recombinant proteins are in the process of production for clinical testing.
TB-drugs include artemisinin, primaquine and its derivative tafenoquine.
These drugs are primarily used for treatment or prophylaxis, but also show
potent killing effects on gct's. The effect oftransmission reductions or clinical
malaria will depend on the rate of transmission and is strongly geographi-
cally determined.
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ITussl Development of resistance dUring antifungal therapy
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In the last decade emergence of resistance during antifungal treatment has
become a well recognized problem in HIV-infected patients receiving long
term prophylaxis and treatment with fluconazole for oropharyngcal candi-
diasis. Molecular typing revealed that in most cases development of
resist:mce of the original C. albicans strain is encountercd. but coexistencc
ofdifferent subpopulations exhibiting various degrees of resist:mce have also
been demonstrated. Risk factors identified for the development offlucona-
zole resistance were low CD4 + counts, previous exposure to the drug and a
total cumulative dose of at least 10 g. No difference in the occurrence of
resistancc could be observed in patients receiving continuous versus inter-
mittent therapy. In non-AIDS patients emergence of azole resistant C.
albicans has been rarely reported. However, an increased incidence of
infections due to Candida spp. intrinsically resistant to fluconazole such as
C. glabrata and C. krusei has been observed in neutropenic patients as well as
in intensive care patients receiving azole drugs for prophylaxis or treatment.
In the last years progress has been made in elucidating the molecular
mechanisms contributing to resistance development of Candida to the
azoles which include enhanced expression of multidrug efllux pumps,
target enzyme overexpression and point mutation of its encoding gene
resulting in decreased affinity to the drug. Recurrences of cryptococcal
meningitis in AIDS patients during maintenance therapy with azoles have
infrequently been associated with the emergcnce of azoic-resistant strains.
Although there are case reports ofinfections due to amphotericin B resistant
yeasts, development of resistance to this antifungal agent appears to bc
uncommon. Flucytosin resistance is known to develop frequently during
monotherapy and is therefore uscd only in combination.
ITuS6! Pharmacodynamics of antifungals
D. Andes
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PK/PD investigations of antibacterials have been used to predict outcomes
against both susceptible and resistent pathogens. For example, studies with
b-lactama have demonstrated that when dosing achieves drug levels exceed-
ing aT> MIC of at least 40% efficacy is observed against bath susceptible
and resistant pathogens. These observations have been important in the
development appropriate dosing strategies and susceptibility breakpoints.
Similar study with antifungal drugs has been limited. Recent studies have
begun to address several important PKfPD questions. Investigation ofthe in-
vivo time course activity ofcurrently available antifungal classes have found
that some demonstrate concentration dependent killing while others do not.
In addition, some antifungal compounds have demonstrated prolonged
persistent effects or postantifungal effects (PAFE) while others have not.
Studies have also demonstrated that different PK/PD parameters predict in-
vivo outcomes for these drugs. Fluconazole demonstrated no in-vivo
concentration dependent killing against susceptible or resistant C. albicans
and in-vivo exposures did, however, result in significant PAFEs. The ratio of
the 24 hr AUC/MIC was the PK/pDP that we, a moat closely associated
with outcomes. Furthermore, similar efficacy was observed against both
susceptible and resistant C. albicans when the magnitude of the 24 hr AUC/
MIC exceeded a value of 25. Similarly, study with f1ucytosine did not
demonstrate concentration dependent killing. Flucytosine therapy did not,
however, result in prolonged PAFEs. T > MIC was the PK/PDP predictive
of efficacy. Amphotericin B demonstrated both concentration dependent
killing and prolonged PAFEs. Peak level/MIC was the parameter best
prcdictive of in-vivo outcomes against Candida species.
These initial studies suggest that further PK/PD analysis of current and
developmental antifungals can offer important dosing Information for initial
clinical trials, effective treatment ofresistant pathogens and the development
of susceptibility breakpoints.
ITuS71synergism between antifungals
J. W. Mouton
Callisius Wilhe/mitla Hospital, Nijmegell, Netherlands
Infections caused by fungi are difficult to treat and arc increasing. Only a few
antimycotic agents are available and partly because of the diversity of fungi,
most species are susceptible to only a few ofthem. Combination therapy is an
alternative. The value and/or efficacy of combination therapy can be
evaluated in vitro, in vivo models and in human trials. Most studies have
been done in vitro by checkerboard type experiments. However, the
interpretation is difficult. Recently, models have become available to fit to
these type of data, such as the Greco model of interaction and the Uli>s
model. The results of these models can be used in simulations to determine
possible effects in vivo. In order to use these models, data have to be of a
quantitative nature. Methods to obtain quantitative readings such as extinc-
rion as a measure of antimycotic effect ming specific dyes are now available
for filamentous fungi. For instance. in vitro synergy has thus been shown for
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itraconazole and terbinafine against clinical isolates ofScedosporium prolijicallS
Results from animal experiments are still scarce and difficult to interpret
because of altered pharmacokinetics in most animals. In humans, synergism
seems to be present for amphotericine combined with flucytosine to treat
infections caused by Cryptococcus spp. It is expected, that new methods to
determine synergism between antifungals will result in a more ratinoal
approach of using combinations of antimycotics in humans.
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@s2] Teell therapy of HCMV infection
Hermann Einsele
Medizillische Klillik II, Eberhard-Karls-Ulliversity, Tubingell, Germally
The reconstitution of HCMV-specific immune responses after allogeneic
SCT has been demonstrated to be protective against the development of
HCMV disease. S. Riddell and P. Greenberg have shown protective
HCMV-specific T cell immunity to be transfered to the recipients of an
allogeneic stem cell transplant by the infusion of donor-derived ex vivo
generated HCMV-specific cytotoxic T cell (CTL) clones. Alternative
strategies to deplete of alloreactive T cells andlor enrich for CMV specific
T cells in donor PBMNCs are increasingly explored and will be discussed.
One possibility is to pulse dendritic cells, the "professional" antigen
presenting cells, with soluble synthetic peptides to induce and propagate
HCMV specific CTLs from HCMV-seropositive and also HCMV-serone-
gative donors. After repetitive specific stimulation T cell lines highly
enriched for HCMV specific T cells can be generated and safely transferred
to patients. In a phase I/II-study recipients of an allograft with persistent
HCMV infection in spite ofprolonged antiviral chemotherapy received I x
I07/m2 polyclonal cell lines without any significant side effects. A transient
reduction of viral load could be documented in all these patients, the
majority of them showed sucessful control ofHCMV infection.
ITuS111 Ribozyme and stem cell gene therapy for the
treatment of HIV infection
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Objectives: Genetic modification ofhematopoietic stem cells with anti-HIV
cat:\lytic RNAs (Ribozymes).
Methods: Hammerhead rihozymes targeting the HIV-I tat and rev tran-
scripts are transduced in the backbone of a murine retroviral vector into
primary hetamotpoietic progenitor cells from HIV-I infected individuals.
The ribozymes are expressed as a polycistronic transcript from the LTR of
the LN retroviral vector. Our hypothesis is that stable transduction of
pluripotent hematopoietic stem cells by ribozyme expressing vectors fol-
lowed by engraftment ofthese cells in the marrow, will ultimately provide a
population ofHIV-I resistant T-cells, monocytes, and dendritic cells. To test
this, we have initiated a clinical trial involving HIV-I infected individuals
who have AIDS related lymphoma using vectors harboring ribozyme or
vector backbone alone transduced into their stem cells. In parallel to the
clinical studies, we are testing new strategies for ribozyme-target co-
localization using chimeric RNA molecules, which harbor our rihozymes
of interest tethered to sequences, which direct the ribozymes to discrete
intracellular localizations.
Results: The clinical trial studies have demonstrated a selective survival of
ribozyme expressing cells within a period of several weeks following bone
marrow transplantation and long term engraftment in at least one patient.
Our new chimeric ribozyme localization studies demonstrate that a nucleo-
lar-localized ribozyme is a potent inhibitor of HIV-I.
Condusions: Ribozyme mediated gene therapy for the treatment ofHIV-I
infection is feasible utilizing hematopoietic stem cells. Potent inhibition of
HIV-I infection by a nucleolar ribozyme suggests nucleolar trafficking of
HIV-I RNAs, opening new targets for anti-HIV-I therapies.
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1TuS131 Assessment of response to antiviral therapy and
antiviral resistance: Hepatitis Band Cvirus
David Gretch
University of WashillgtOtl, Laboratory Medicine, Settle, Washingtoll 98104,
Utlited States
Chronic viral hepatitis due to hepatitis B virus (HBV) or hepatitis C virus
(HCV) infection is a major cause of morbidity and mortality, effecting
hundreds of millions ofindividuals worldwide. Long term complications of
untreated chronic viral hepatitis include progressive liver disease and
hepatocellular carcinoma. Interferon alpha has historically been the first
line treatment for chronic viral hepatitis. However, this therapy is only
moderately effective and is often limited by side effects. Newer agents
including nucleoside analogs for chronic hepatitis B. and ribavirin in
combination with interferon for chronic hepatitis C, have shown promise
for improving response rates. In chronic hepatitis B, antigen tests (HBeAg,
HBsAg), antibody tests (anti-HBs, anti-HBe) and nucleic acid tests (HBV
DNA) are used to monitor response to antiviral therapy, while in chronic
hepatitis C, treatment response is monitored by following qualitative andlor
quantitative HCV RNA in serum. In general, successful treatment of
chronic hepatitis B results in disappearance of the viral antigens and HBV
DNA, and seroconversion to positivc anti-HBs and anti-HBe status. In
chronic hepatitis C, successful treatment is associated with clearance ofHCV
RNA from serum during the first 3-6 months of therapy, and absence of
detectable viral RNA in serum 6 months after cessation of therapy. In both
cases, such responses predict sustained clinical remissions and histological
improvement of liver disease. Drug resistance to nucleoside analog mono-
therapy is well documented in chronic hepatitis B, and appears to result from
critical mutations within the HBV polymerase gene. The role of viral
mutations in detcrmining sensitivity or resistance of HBV and HCV to
interferon therapy is less well defined, primarily due to a lack of suitable
culture systems for phenotypic characterization of putative resistant viral
populations.
ITuS161 Detection of drug-resistant HCMV strains by
monitoring response to antiviral treatment in
immunocompromised patients
G. Gema, F. Baldanti, D. Lilleri, A. Sarasini
Servizio di Virologia, fRCCS Policlinico S. Malleo, Pavia, ftaly
Monitoring of response to treatment by quantitative determination of
antigenemia viremia and leukoDNAemia is the most useful tool for early
detection ofdrug-resistant HCMV strains in immunocompromised patients.
In fact, lack ofreduction or increase in level of measured viral parameters in
blood during therapy suggests the unrestricted viral replication. In parti-
cular. while antigenemia and leukoDNAemia quantitate viral components,
viremia is a direct measure of the amount ofinfectious virus and of the virus
replicative potential during treatment. However, delayed reduction in viral
load during treatment is not invariably associated with the emergence of a
drug-resistant HCMV strain. Thus, rapid confirmatory assays are needed in
order to decide treatment change. A simplified immediate- early plaque-
reduction assay using blood leukocytes as inoculum, allows a rapid (4-6
days) screening for drug-resistance. Detection of specific mutations in
HCMV UL97 or UL54 genes directly in clinical specimens by PCR-based
methods or sequencing allows demonstration of the presence of drug-
resistant strains within 2-3 days. In AIDS patients, disseminated HCMV
infections have been treated mostly in the presence of specific symptoms,
whereas in solid organs or bone marrow recipients adoption of preemptive
therapy protocols implies initiation ofanti-HCMV treatment when patients
are still in the asymptomatic phase of the infection. This difference along
with the need in the recent past of prolonged anti-HCMV maintenance
treatment in AIDS patients might account for the reported greater pre-
valence of HCMV drug-resistant strains in this patient population with
respect to transplant recipients. However. the recent introduction of potent
antiretroviral combination protocols was followed by a drastic reduction in
the prevalence ofHCMV infections in AIDS patients, with a further reduced
number of reported new resistant HCMV strains. In the transplantation
settings, several anedoctical reports ofHCMV drug-resistant strains points to
a possible emerging problem in the near future.
